Preprint / Version 1

Early onset of Alzheimer's is on the rise - Evidence and Implications


  • Aldan Joseph High School student



Alzheimer's, MDD, SSRIs, Diets


The prevalence of early-onset Alzheimer's Disease (AD) and Major Depressive Disorder (MDD)
has demonstrated an escalating trajectory. This warrants an investigation into their intricate
connections. This review will assess the relationship among AD, MDD, and their associated
medication, specifically Selective Serotonin Reuptake Inhibitors (SSRIs). The overarching
hypothesis suggests that diet significantly contributes to depression by modulating tryptophan
metabolism, and SSRIs can significantly stunt AD progression. Therefore, this review will
examine three aspects: the biochemistry of depression and how it relates to the progression of
AD; how diet is linked to MDD and whether this is predominant in a younger age range; and the
potential effectiveness of the SSRIs fluoxetine (FLX) and citalopram as a treatment to inhibit AD


De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer’s disease. Subcell

Biochem. 2012;65:329–52.

Finder VH. Alzheimer’s disease: a general introduction and pathomechanism. J

Alzheimers Dis. 2010;22 Suppl 3:5–19.

Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. In: StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 16]. Available from:

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018 Jan;25(1):59–70.

Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s Disease: Past, Present, and Future. J

Int Neuropsychol Soc. 2017 Oct;23(9–10):818–31.

Statista [Internet]. [cited 2023 Nov 25]. Early-onset Alzheimer’s diagnosis rates by age

U.S. 2013-2017. Available from:

Mendez MF. Early-Onset Alzheimer Disease. Neurol Clin. 2017 May;35(2):263–81.

Goodwin RD, Dierker LC, Wu M, Galea S, Hoven CW, Weinberger AH. Trends in U.S.

Depression Prevalence From 2015 to 2020: The Widening Treatment Gap. Am J Prev Med.


Shad MU, Muddasani S, Rao U. Gray matter differences between healthy and depressed

adolescents: a voxel-based morphometry study. J Child Adolesc Psychopharmacol. 2012


Mercadante AA, Tadi P. Neuroanatomy, Gray Matter. In: StatPearls [Internet]. Treasure

Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 16]. Available from:

Serra L, Cercignani M, Lenzi D, Perri R, Fadda L, Caltagirone C, et al. Grey and white

matter changes at different stages of Alzheimer’s disease. J Alzheimers Dis.


O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease.

Annu Rev Neurosci. 2011;34:185–204.

Rajmohan R, Reddy PH. Amyloid-Beta and Phosphorylated Tau Accumulations Cause

Abnormalities at Synapses of Alzheimer’s disease Neurons. J Alzheimers Dis.


Zhang Y wu, Thompson R, Zhang H, Xu H. APP processing in Alzheimer’s disease. Mol

Brain. 2011 Jan 7;4:3.

Cappai R, White AR. Amyloid beta. Int J Biochem Cell Biol. 1999 Sep;31(9):885–9.

Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta

protein assembly in the brain impairs memory. Nature. 2006 Mar 16;440(7082):352–7.

Pîrşcoveanu DFV, Pirici I, Tudorică V, Bălşeanu TA, Albu VC, Bondari S, et al. Tau

protein in neurodegenerative diseases - a review. Rom J Morphol Embryol. 2017;58(4):1141–50.

Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by

asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat

Med. 2014 Nov;20(11):1254–62.

Jacka FN, Cherbuin N, Anstey KJ, Butterworth P. Dietary patterns and depressive

symptoms over time: examining the relationships with socioeconomic position, health

behaviours and cardiovascular risk. PLoS One. 2014;9(1):e87657.

Zamani B, Zeinalabedini M, Nasli Esfahani E, Azadbakht L. Can Following Paleolithic and

Mediterranean Diets Reduce the Risk of Stress, Anxiety, and Depression: A Cross-Sectional

Study on Iranian Women. J Nutr Metab. 2023;2023:2226104.

Shafiei F, Salari-Moghaddam A, Larijani B, Esmaillzadeh A. Mediterranean diet and

depression: reanalysis of a meta-analysis. Nutr Rev. 2023 Jun 9;81(7):889–90.

Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S. Nutritional aspects of

depression. Cell Physiol Biochem. 2015;37(3):1029–43.

Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors

(SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem.


Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. In: StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 18]. Available from:

Sangkuhl K, Klein TE, Altman RB. Selective serotonin reuptake inhibitors pathway.

Pharmacogenet Genomics. 2009 Nov;19(11):907–9.

Abu-Elfotuh K, Al-Najjar AH, Mohammed AA, Aboutaleb AS, Badawi GA. Fluoxetine

ameliorates Alzheimer’s disease progression and prevents the exacerbation of cardiovascular

dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering

TLR4/NLRP3 inflammasome signaling pathway. Int Immunopharmacol. 2022 Mar;104:108488.

Proudman D, Greenberg P, Nellesen D. The Growing Burden of Major Depressive

Disorders (MDD): Implications for Researchers and Policy Makers. Pharmacoeconomics. 2021


2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022 Apr;18(4):700–89.

2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023


Paul-Savoie E, Potvin S, Daigle K, Normand E, Corbin JF, Gagnon R, et al. A deficit in

peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin

J Pain. 2011;27(6):529–34.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive

disorder. Nat Rev Dis Primers. 2016 Sep 15;2:16065.

aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major

depressive disorder. CMAJ. 2009 Feb 3;180(3):305–13.

Pandya M, Altinay M, Malone DA, Anand A. Where in the brain is depression? Curr

Psychiatry Rep. 2012 Dec;14(6):634–42.

Zhang FF, Peng W, Sweeney JA, Jia ZY, Gong QY. Brain structure alterations in

depression: Psychoradiological evidence. CNS Neurosci Ther. 2018 Nov;24(11):994–1003.

Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, et al.

Alzheimer’s Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci.


Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and

Treatment. Molecules. 2020 Dec 8;25(24):5789.

Maurya R, Bhattacharjee G, Khambhati K, Gohil N, Singh P, Mani I, et al. Amyloid

precursor protein in Alzheimer’s disease. Prog Mol Biol Transl Sci. 2023;196:261–70.

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: structure,

biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017


Opitz B. Memory function and the hippocampus. Front Neurol Neurosci. 2014;34:51–9.

Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and

Alzheimer’s disease. Biochim Biophys Acta. 2005 Jan 3;1739(2–3):216–23.

Valiron O, Caudron N, Job D. Microtubule dynamics. Cell Mol Life Sci. 2001


Dolan PJ, Johnson GVW. The role of tau kinases in Alzheimer’s disease. Curr Opin Drug

Discov Devel. 2010 Sep;13(5):595–603.

Dafsari FS, Jessen F. Depression-an underrecognized target for prevention of dementia

in Alzheimer’s disease. Transl Psychiatry. 2020 May 20;10(1):160.

Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and

brain structure. Neurology. 2009 Dec 1;73(22):1899–905.

Chi S, Yu JT, Tan MS, Tan L. Depression in Alzheimer’s disease: epidemiology,

mechanisms, and management. J Alzheimers Dis. 2014;42(3):739–55.

Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, et al.

High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review.

Cells. 2021 Nov 14;10(11):3164.

Dunford EK, Popkin B, Ng SW. Junk Food Intake Among Adults in the United States. J

Nutr. 2022 Feb 8;152(2):492–500.

Liu J, Lee Y, Micha R, Li Y, Mozaffarian D. Trends in junk food consumption among US

children and adults, 2001-2018. Am J Clin Nutr. 2021 Sep 1;114(3):1039–48.

Zielińska M, Łuszczki E, Dereń K. Dietary Nutrient Deficiencies and Risk of Depression

(Review Article 2018-2023). Nutrients. 2023 May 23;15(11):2433.

Schwingshackl L, Morze J, Hoffmann G. Mediterranean diet and health status: Active

ingredients and pharmacological mechanisms. Br J Pharmacol. 2020 Mar;177(6):1241–57.

Lin K, Li Y, Toit ED, Wendt L, Sun J. Effects of Polyphenol Supplementations on

Improving Depression, Anxiety, and Quality of Life in Patients With Depression. Front

Psychiatry. 2021;12:765485.

Gillen MM. Associations between positive body image and indicators of men’s and

women’s mental and physical health. Body Image. 2015 Mar;13:67–74.

Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the Mediterranean

Diet for Long-Term Weight Loss. Am J Med. 2016 Apr;129(4):407-415.e4.

Jamka M, Kulczyński B, Juruć A, Gramza-Michałowska A, Stokes CS, Walkowiak J. The

Effect of the Paleolithic Diet vs. Healthy Diets on Glucose and Insulin Homeostasis: A

Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020 Jan


Ghaedi E, Mohammadi M, Mohammadi H, Ramezani-Jolfaie N, Malekzadeh J,

Hosseinzadeh M, et al. Effects of a Paleolithic Diet on Cardiovascular Disease Risk Factors: A

Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2019 Jul


Lindseth G, Helland B, Caspers J. The effects of dietary tryptophan on affective

disorders. Arch Psychiatr Nurs. 2015 Apr;29(2):102–7.

Kikuchi AM, Tanabe A, Iwahori Y. A systematic review of the effect of L-tryptophan

supplementation on mood and emotional functioning. J Diet Suppl. 2021;18(3):316–33.

Scoditti E, Tumolo MR, Garbarino S. Mediterranean Diet on Sleep: A Health Alliance.

Nutrients. 2022 Jul 21;14(14):2998.

Bakshi A, Tadi P. Biochemistry, Serotonin. In: StatPearls [Internet]. Treasure Island (FL):

StatPearls Publishing; 2023 [cited 2023 Jul 15]. Available from:

Appleton J. The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health.

Integr Med (Encinitas). 2018 Aug;17(4):28–32.

Sahu A, Gopalakrishnan L, Gaur N, Chatterjee O, Mol P, Modi PK, et al. The

-Hydroxytryptamine signaling map: an overview of serotonin-serotonin receptor mediated

signaling network. J Cell Commun Signal. 2018 Dec;12(4):731–5.

Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Dougherty DM.

L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications. Int

J Tryptophan Res. 2009 Mar 23;2:45–60.

Whitford GM. Alzheimer’s disease and serotonin: a review. Neuropsychobiology.


Popa TA, Ladea M. Nutrition and depression at the forefront of progress. J Med Life.

Dec 15;5(4):414–9.

Mdawar B, Ghossoub E, Khoury R. Selective serotonin reuptake inhibitors and

Alzheimer’s disease. Neural Regen Res. 2020 Jan;15(1):41–6.

Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective

Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug


Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, et al.

Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid

receptor. Mol Psychiatry. 2011 Jul;16(7):738–50.

Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin

reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen

Psychiatry. 2006 Nov;63(11):1217–23.

Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim

Care Companion J Clin Psychiatry. 2001 Feb;3(1):22–7.

Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome.

Handb Clin Neurol. 2018;157:663–75.

Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of

patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin

Psychopharmacol. 2007 Feb;27(1):67–70.

Reddy AP, Yin X, Sawant N, Reddy PH. Protective effects of antidepressant citalopram

against abnormal APP processing and amyloid beta-induced mitochondrial dynamics,

biogenesis, mitophagy and synaptic toxicities in Alzheimer’s disease. Hum Mol Genet. 2021

May 29;30(10):847–64.

Reddy AP, Sawant N, Morton H, Kshirsagar S, Bunquin LE, Yin X, et al. Selective

serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against

amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic

toxicities in a mouse model of Alzheimer’s disease. Hum Mol Genet. 2021 May


Elsworthy RJ, Crowe JA, King MC, Dunleavy C, Fisher E, Ludlam A, et al. The effect of

citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human

hNSC-derived neurons. Transl Psychiatry. 2022 Jul 18;12(1):285.

Vrahatis AG, Skolariki K, Krokidis MG, Lazaros K, Exarchos TP, Vlamos P.

Revolutionizing the Early Detection of Alzheimer’s Disease through Non-Invasive Biomarkers:

The Role of Artificial Intelligence and Deep Learning. Sensors (Basel). 2023 Apr 22;23(9):4184.